Abstract
Resistant hypertension (RHTN) includes patients whose blood pressure (BP) is controlled with the use of four or more antihypertensive medications, and is referred to as ‘controlled resistant hypertension’ (CRH). While specifically comparing patients with CRH and uncontrolled resistant hypertension (UCRH), we hoped to identify distinguishing characteristics that would provide insight into factors contributing to resistance to antihypertensive therapies. RHTN patients were identified as controlled (CRH, n=43) or uncontrolled (UCRH, n=47). No statistical differences were observed between the CRH and UCRH subgroups with respect to age and gender. The body mass index, aldosterone–renin ratio and pulse wave velocity (PWV) were significantly higher in UCRH patients. Although both subgroups showed increased cardiac mass, left ventricular mass index was significantly higher in UCRH compared with CRH patients. Multivariate linear regression analysis indicated that PWV was significantly dependent on age in both UCRH and CRH patients; however, the influence of ageing was more pronounced in the former subgroup. Older age, greater vascular stiffness, higher aldosterone levels and greater left ventricular hypertrophy were significantly associated with lack of BP control in patients with RHTN. These findings suggest important possibilities in terms of preventing and better treating RHTN.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510–e526.
Lloyd-Jones DM, Evans JC, Levy D . Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294 (4): 466–472.
Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S et al. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens 2007; 25 (10): 2131–2137.
Lim MA, Townsend RR . Arterial compliance in the elderly: its effect on blood pressure measurement and cardiovascular outcomes. Clin Geriatr Med 2009; 25 (2): 191–205.
Scuteri A, Coluccia R, Castello L, Nevola E, Brancati AM, Volpe M . Left ventricular mass increase is associated with cognitive decline and dementia in the elderly independently of blood pressure. Eur Heart J 2009; 30 (12): 1525–1529.
Kotchen TA, Grim CE, Kotchen JM, Krishnaswami S, Yang H, Hoffmann RG et al. Altered relationship of blood pressure to adiposity in hypertension. Am J Hypertens 2008; 21 (3): 284–289.
Sowers JR, Whaley-Connell A, Epstein M . Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150 (11): 776–783.
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P . Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40 (6): 892–896.
Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP . Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22 (11): 2217–2226.
Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky Jr J . Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17 (5): 349–352.
Duprez DA . Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens (Greenwich) 2007; 9 (1 Suppl 1): 13–18.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560–2572.
Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G . Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol 1994; 34 (9): 944–949.
Morisky DE, Green LW, Levine DM . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24 (1): 67–74.
de Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, Sabha M, Moreno Jr H . Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. Am J Health Syst Pharm 2007; 64 (18): 1955–1961.
White WB, Anwar YA . Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adults. Blood Press Monit 2001; 6 (2): 107–110.
Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26 (3): 485–490.
Sahn DJ, DeMaria A, Kisslo J, Weyman A . Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58 (6): 1072–1083.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18 (12): 1440–1463.
Avolio AP, Deng FQ, Li WQ, Luo YF, Huang ZD, Xing LF et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 1985; 71 (2): 202–210.
Kelly R, Hayward C, Avolio A, O’Rourke M . Noninvasive determination of age-related changes in the human arterial pulse. Circulation 1989; 80 (6): 1652–1659.
Lamounier-Zepter V, Ehrhart-Bornstein M . Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep 2006; 8 (1): 30–34.
Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K . Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43 (2): 358–363.
Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007; 293 (4): H2009–H2023.
Brown NJ . Aldosterone and vascular inflammation. Hypertension 2008; 51 (2): 161–167.
Wehling M, Christ M, Theisen K . Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am J Physiol 1992; 263 (5 Part 1): E974–E979.
Goodfriend TL, Calhoun DA . Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43 (3): 518–524.
Williams B . The aorta and resistant hypertension. J Am Coll Cardiol 2009; 53 (5): 452–454.
Bouthier JD, De Luca N, Safar ME, Simon AC . Cardiac hypertrophy and arterial distensibility in essential hypertension. Am Heart J 1985; 109 (6): 1345–1352.
Liu ZR, Ting CT, Zhu SX, Yin FC . Aortic compliance in human hypertension. Hypertension 1989; 14 (2): 129–136.
Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49 (4): 839–845.
Ubaid-Girioli S, Ferreira-Melo SE, Souza LA, Nogueira EA, Yugar-Toledo JC, Coca A et al. Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) 2007; 9 (10): 770–774.
Struijker Boudier HA, Cohuet GM, Baumann M, Safar ME . The heart, macrocirculation and microcirculation in hypertension: a unifying hypothesis. J Hypertens Suppl 2003; 21 (3): S19–S23.
Schiffrin EL, Touyz RM . From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004; 287 (2): H435–H446.
Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR et al. Aldosterone excess or escape: treating resistant hypertension. J Clin Hypertens (Greenwich) 2009; 11 (5): 245–252.
Acknowledgements
This study was supported by FAPESP, SP, Brazil. H Moreno Jr, V Nasser Figueiredo and T Quinaglia were supported by Conselho Nacional de Pesquisa (CNPq) and CAPES (Brazil).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Martins, L., Figueiredo, V., Quinaglia, T. et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens 25, 532–538 (2011). https://doi.org/10.1038/jhh.2010.95
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2010.95
Keywords
This article is cited by
-
The Impact of Obesity on the Resolution of Hypertension Following Adrenalectomy for Primary Hyperaldosteronism
World Journal of Surgery (2023)
-
Association between arterial stiffness and sleep apnoea in patients with resistant hypertension
Journal of Human Hypertension (2022)
-
Weight Loss Medications in the Treatment of Obesity and Hypertension
Current Hypertension Reports (2019)
-
Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men’s Issue?
Current Hypertension Reports (2019)
-
Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?
Current Hypertension Reports (2018)